Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

Victoria Plamadeala,Joseph L Kelley, John K Chan,Thomas C Krivak,Michael J Gabrin,Stacey L Brower,Matthew A Powell,Thomas J Rutherford,Robert L Coleman

Gynecologic Oncology（2015）

Cited 8|Views8
No score
Abstract
•The use of chemoresponse assay to inform treatment decisions in recurrent ovarian cancer has the potential to be cost-effective.•The use of the chemoresponse assay has the potential to be cost-effective in both platinum sensitive and platinum-resistant patients.
More
Translated text
Key words
Chemoresponse assay,Cost-effectiveness,Ovarian cancer,Chemotherapy sensitivity and resistance assay (CSRA),Markov transition model
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined